Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Advantest | Hut 8 | Pfizer | |
|---|---|---|---|
| Moat rating | wide A disclosed share that rose while margin expanded. The FY2025 Annual Securities Report and Business Report (84th term, filed 2026-06-26) lists as FY2025 progress: 'Further expanded our market share in the semiconductor tester (ATE) market (CY2024: 58%; CY2025: 65%)', earned on net sales of ¥1,128,610 million at an operating income to net sales ratio of 44.2%, 'an increase of 14.9 percentage points from the previous fiscal year'. The share is a company metric and the filing says so — 'the ratio of Advantest's semiconductor tester sales to the overall size of the semiconductor tester market', where 'The semiconductor tester market size is estimated independently by Advantest based on certain assumptions and available information'. The same filing names seven principal tester competitors (Teradyne, Inc., CCTech, Accotest, YC Corp., Cohu, Inc., UniTest Co., Ltd. and EXICON Ltd.), so this is a lead held against a named field rather than an empty one. | narrow The FY2025 10-K says 'we believe we have established a defensible competitive advantage through our power-first, innovation-driven strategy', resting on a power-native team, an application-agnostic framework for digital infrastructure design, end-to-end greenfield development capabilities, and the use of ASIC compute builds to rapidly and cost-effectively secure and monetize power. What separates this from no moat is scarce power: the filing says demand for energy capacity continues to outpace supply and that 'grid interconnection bottlenecks have further constrained access to power and digital infrastructure development', and Hut 8 reports 330 MW of utility capacity under construction at River Bend, commercialized in December 2025 through a 15-year triple-net lease supporting 245 MW of IT capacity, plus 1,230 MW of utility capacity under development. The same filing says 'The industries in which we operate are highly competitive and continuously evolving.', warns that these factors 'might not provide the competitive advantage we anticipate, or if they do, such competitive advantage might not endure', cites the River Bend lease (valued at $7.0 billion over the base term) as an example of expecting a significant portion of revenue from a limited number of customers, and says the company has not maintained consistent profitability. That supports narrow at most, not wide. | eroding The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed. |
| Moat type | intangibles ip What management itself names as the source of the position is a proprietary platform. The July 29, 2026 Q1 FY2026 results briefing states: 'Our leading SoC Test platform, V93000, has been widely adopted across a broad range of customers in the increasingly complex AI semiconductor markets, where advanced packaging technologies including GPUs, ASICs, and CPUs are being adopted. It serves as a key foundation that underpins our competitive advantage.' The 84th-term report shows the spend behind it: R&D was approximately ¥71.4 billion in FY2024 and ¥78.1 billion in FY2025, 'The number of employees in its research and development division is approximately 30% of the Advantest workforce', and in the Test System Business Segment 'a large and ongoing investment in research and development is necessary in order to maintain market competitiveness'. Its stated IP mitigation is that 'Advantest strategically and proactively files patent applications during product development and prior to product shipment'. | cost scale The 10-K says 'we believe success depends on the ability to secure scarce assets like power, data center equipment, and customers', and places part of its claimed edge in 'our ability to use ASIC compute infrastructure development to rapidly and cost-effectively secure and monetize power'. Its examples: Vega was energized less than a year after acquisition for an all-in cost of about $455,000 per megawatt, which the filing calls 'a fraction of traditional data center costs', and Salt Creek was completed for about $250,000 per MW; Vega also has immediate access to some of the lowest locational wholesale power prices in North America. These are low-redundancy ASIC compute builds, which the 10-K says carry relatively low capital intensity by design. The 'fraction of traditional data center costs' comparison is against a different facility tier, and the filing gives no peer cost comparison and no cost figure for its AI campuses. | intangibles ip The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section. |
| Leadership | clear leader The 84th-term report discloses Advantest's tester-market share at 65% in CY2025, up from 58% in CY2024, and carries the same 65% among its disclosed management metrics against a target of '58% or more'; the filing defines it as Advantest's semiconductor tester sales over a market size 'estimated independently by Advantest based on certain assumptions and available information'. The July 29, 2026 briefing names the platform behind that share — V93000, 'widely adopted across a broad range of customers in the increasingly complex AI semiconductor markets'. Teradyne, Inc. heads the filing's list of principal tester competitors. | fast follower The 10-K says 'For example, we signed our first large scale single tenant AI data center lease and commenced construction of the site at our River Bend campus.', offered under the statement that to remain competitive with peers it may need to modify aspects of its business model. River Bend was commercialized in December 2025 through a 15-year triple-net lease supporting 245 MW of IT capacity; Fluidstack is expected to serve as tenant and Google is expected to provide a financial backstop, and initial delivery is targeted for Q2 2027. On speed, the filing says 'Through early engagement with Entergy Louisiana, we assumed key interconnection and development functions typically managed by the utility, such as the development of transmission and distribution infrastructure, materially accelerating originally quoted power delivery timelines.', and that Vega was energized 'less than a year after acquiring it'. It also warns that Hut 8 competes against companies 'that may be more established or have greater financial and other resources and/or expertise'. That describes a newer entrant moving quickly, not an established leader. | co leader The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.' |
| Pricing power | strong Q1 FY2026 gross profit was ¥255,553 million on net sales of ¥367,473 million, and the July 29, 2026 briefing states the resulting figure itself: 'Gross margin reached 69.5%', with 'an operating margin of 51.7%'. Management attributes that level to 'a favorable sales mix and limited inventory valuation losses amid the robust demand environment', not to price, and guides FY2026 full-year gross margin to 66–67% and operating margin to 49.4% after incorporating 'the impact of higher component costs, particularly for memory-related components'. FY2025 closed at a 44.2% operating margin, up 14.9 points year on year, on sales up 44.7%. | weak The 10-K says ASIC compute, run through American Bitcoin, can only be profitable if hardware and electricity costs are below the price of the Bitcoin mined, which makes it a price-taking business. It also says Traditional Cloud and AI Cloud compete with cloud services providers for customers, and that the company has not maintained consistent profitability. River Bend's contracted triple-net lease economics are not in service yet; initial delivery is targeted for Q2 2027. | weak Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price. |
| Summary | Advantest sells the test step that certifies silicon before it ships, and its position there is disclosed rather than inferred: its own tester-market-share metric moved from 58% in CY2024 to 65% in CY2025 (84th-term Annual Securities Report), against a market size the filing says Advantest estimates itself. The lead is concentrated in SoC test — the July 29, 2026 briefing calls V93000 'our leading SoC Test platform' and 'a key foundation that underpins our competitive advantage' — and the customer base runs straight into the AI chain: NVIDIA International, Inc. was ¥228,273 million, or 20.2%, of FY2025 consolidated net sales, having been below the filing's 10% disclosure threshold the prior year, with Taiwan Semiconductor Manufacturing Co., Ltd. at ¥124,922 million, or 11.1%. Economics moved with it: FY2025 operating margin was 44.2%, up 14.9 points, and Q1 FY2026 gross margin reached 69.5%, which management attributes to 'a favorable sales mix and limited inventory valuation losses amid the robust demand environment' rather than to price. The counterweights sit in the same documents. The 84th-term report's customer-trust risk factor warns that if Advantest fails to meet expectations on ramp-up and post-sales service, 'the maintenance or expansion of Advantest's market share may be constrained'; it names separate competitor sets in test handlers (Hon. Precision, CCTech, Cohu, TechWing) and device interfaces (TSE, ISC, BeLINK) where no share is disclosed at all; and the July 29, 2026 briefing guides FY2026 full-year gross margin down to 66–67% having 'incorporated the impact of higher component costs, particularly for memory-related components, mainly in the second half of the fiscal year'. | Per its FY2025 10-K, Hut 8 is a power-first infrastructure developer. It originates powered land and interconnections, uses ASIC compute builds, which the filing says combine relatively low capital intensity with rapid deployment, as a transitional load to monetize sites sooner, and aims to transition suitable power assets to higher-return uses; its River Bend campus was commercialized through a 15-year AI data center lease. The filing claims a defensible advantage but warns it might not provide the advantage anticipated, or might not endure. It says Hut 8 competes for powered land with digital infrastructure developers and large-scale Bitcoin miners, and its first AI campus is still under construction. Its majority-owned Bitcoin miner, American Bitcoin, can only be profitable when mining costs are below the price of the Bitcoin mined, and the filing says it believes American Bitcoin must keep acquiring miners to keep up with a growing global network hashrate. | Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book. |
| Chain position | Back-end capital equipment: Advantest's testers certify devices after fabrication, and the 84th-term report's FY2025 major-customer table puts NVIDIA International, Inc. at 20.2% and Taiwan Semiconductor Manufacturing Co., Ltd. at 11.1% of consolidated net sales, with overseas sales 97.8% of the total. | Power-first developer building AI data center capacity, beginning with River Bend under a 15-year lease (Fluidstack is the expected tenant and Google is expected to provide a financial backstop; initial delivery is targeted for Q2 2027), and runs Bitcoin mining through majority-owned American Bitcoin. | Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.42 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.01 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.17 at weight 0.20 · swarm bearish Editorial prior, not backtested. |